State Street SPDR S&P Pharmaceuticals ETF
XPH
80 hedge funds and large institutions have $143M invested in State Street SPDR S&P Pharmaceuticals ETF in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
36% more capital invested
Capital invested by funds: $105M → $143M (+$38M)
11% more funds holding
Funds holding: 72 → 80 (+8)
3.65% more ownership
Funds ownership: 47.58% → 51.23% (+3.7%)
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMI
Factory Mutual Insurance
Waltham,
Massachusetts
|
+$10M |
| 2 |
Goldman Sachs
New York
|
+$5.73M |
| 3 |
Morgan Stanley
New York
|
+$3.97M |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$1.43M |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
CX Institutional
Auburn,
Indiana
|
-$1.69M |
| 2 |
JP Morgan Chase
New York
|
-$1.38M |
| 3 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$1.36M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.06M |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$868K |
XPH Hedge Fund Activity: Q4 2020 in Review
80 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2020, worth a combined $143M — up 36% from $105M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XPH positions and 5 closed out — a net gain of 8 holders — while 15 added to existing stakes and 26 trimmed.
The largest buyer was Factory Mutual Insurance, opening a new position worth an estimated $10M. The largest seller was CX Institutional, cutting an estimated $1.69M.
- 80 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2020, up from 72 in Q3 2020.
- Funds reported $143M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2020, up 36% quarter-over-quarter.
- 13 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2020 and 5 closed out, a net change of +8 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2020 was Factory Mutual Insurance, an estimated $10M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2020 was CX Institutional, an estimated $1.69M sold.
Based on aggregated 13F filings for Q4 2020.